Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3011 for Acute Gouty Arthritis
NCT07842497Phase 2Not yet recruiting
- Sponsor
- Innovent Biologics
- Start
- Oct 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
A Phase 2 trial of IBI3011 in acute gouty arthritis, sponsored by Innovent Biologics. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
IBI3011
03
Conditions
acute gouty arthritis
Beyond the preview
Go deeper on NCT07842497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07842497.